A Multi-Center Group to Study Acute Liver Failure in Children

Status Completed

Clinical Trial Summary

The PALF study group began with 20 sites and now continues with 12 sites (11 in the United States and 1 in Canada) in the new funding period. The primary objective of the Pediatric Acute Liver Failure (PALF) study is to collect, maintain, analyze, and report clinical, epidemiological, and outcome data in children with ALF, including information derived from biospecimens.

Clinical Trial Description

The PALF study group will collect clinical, epidemiological and outcome data on children with ALF. This information will be used to develop methods to predict whether a child will recover from the illness without the need for a liver transplant or other life-saving procedure. We believe the methods to predict survival will vary with different patient age groups, but that diagnosis, multi-system organ failure, degree of encephalopathy and level of coagulopathy will be important regardless of patient age. Biological samples, such as blood and liver tissue, will provide opportunities to identify subgroups of patients who have unique treatment requirements and outcomes. In addition, we hope to identify unrecognized mechanisms of liver injury resulting in ALF in children. Eligible study participants will be invited to participate in neurocognitive testing. Since patients that develop acute liver failure experience varying levels of hepatic encephalopathy and cerebral edema, we suspect that there may be residual sub-clinical neurological injury that compromises long-term neurocognitive function. Detailed neurocognitive testing has never been performed in a cohort of children that survive acute liver failure and this study seeks to close that information gap by defining the spectrum of neurocognitive outcomes in this population. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00986648
Study type	Observational
Source	University of Pittsburgh
Contact
Status	Completed
Phase	N/A
Start date	January 2000
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01559519` - Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy	Phase 4
Terminated	`NCT01846806` - The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.	N/A
Recruiting	`NCT01178372` - Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis	Phase 4
Completed	`NCT00740142` - Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy	Phase 4
Completed	`NCT00914056` - A Study of Controlled Lactulose Withdrawal	N/A
Completed	`NCT00558038` - Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy	Phase 2
Completed	`NCT00986895` - A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group	Phase 1
Completed	`NCT00287235` - Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)	N/A
Recruiting	`NCT05539027` - Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy	Phase 4
Recruiting	`NCT04096014` - Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy	N/A
Completed	`NCT05526404` - Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration	N/A
Completed	`NCT04082780` - Rifamycin in Minimal Hepatic Encephalopathy	Phase 2
Enrolling by invitation	`NCT06367127` - Utility of the Clamping Bean Test (CBT) for Covert Hepatic Encephalopathy Screening
Active, not recruiting	`NCT05425316` - Speech in Hepatic Encephalopathy (HE)
Recruiting	`NCT04415294` - Flicker App for Minimal Hepatic Encephalopathy
Not yet recruiting	`NCT06072521` - Efficacy of Lactoferrin as an Adjunct Therapy in Patients With Hepatic Encephalopathy	Phase 2
Completed	`NCT02636647` - Fecal Transplant in Recurrent Hepatic Encephalopathy	Phase 1
Withdrawn	`NCT02086825` - A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure	Phase 3
Completed	`NCT01446523` - S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE	N/A
Completed	`NCT01218568` - Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial	N/A